|
DGAP-News: LPKF Laser & Electronics Aktiengesellschaft
/ Key word(s): Miscellaneous
Garbsen, November 30, 2021 - Technology company LPKF today opened a bio lab for a technology platform for single cell analysis at the company's headquarters in Garbsen, Germany.
In its 45-year history, the company has repeatedly developed groundbreaking technologies and opened up new markets in the electronics, research and development, automotive and solar sectors. Now LPKF has developed a platform that will enable future customers in the biotechnology and pharmaceutical industries to perform single-cell screenings quickly and efficiently. ARRALYZE combines biomedical research with software and precision technology and is designed to accelerate the development of personalized medicine, e.g. in the field of cancer therapies. Dr. Robin Krueger is head of ARRALYZE. He studied chemistry and biochemistry and worked early on with optically switchable proteins in hospital germs. "We know that tumors have individual characteristics and are influenced by genes and other physiological properties. For this reason, no one should get a standard cancer therapy, but one that is tailored to them personally." Krueger and his team of collaborators are convinced that ARRALYZE will make the development of modern medication much more cost-effective, thus enabling the widespread use of personalized medicine. The biolab is furnished with specialized equipment for the production and analysis of cell cultures. "The biolab is essential for us to understand the needs and problems of our ARRALYZE customers and to be able to offer practical solutions," says Krueger. "This is what sets us apart from other companies in this complex field." For Britta Schulz, member of the Management Board and head of the Development segment, the development of ARRALYZE technology in less than 3 years is a demonstration to LPKF's unwavering innovative strength. "With our LIDE technology for structuring glass and our expertise in optics, precision engineering and software, we are now bringing a product to market that will set new standards in biotechnology," says Schulz. About LPKF LPKF Laser & Electronics AG is a leading supplier of laser-based solutions for the technology industry. LPKF laser systems are vital in the manufacture of printed circuit boards, microchips, automotive parts, solar panels, and many other components. Founded in 1976, the company is headquartered in Garbsen near Hanover, Germany, and is active worldwide through subsidiaries and agencies. The shares of LPKF Laser & Electronics AG are listed on the SDAX of the Deutsch Börse stock exchange (ISIN 0006450000). Contact: Bettina Schäfer, Department Manager Group Communication & Investor Relations
30.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | LPKF Laser & Electronics Aktiengesellschaft |
| Osteriede 7 | |
| 30827 Garbsen | |
| Germany | |
| Phone: | +49 (0) 5131 7095-0 |
| Fax: | +49 (0) 5131 7095-95 |
| E-mail: | investorrelations@lpkf.com |
| Internet: | www.lpkf.com |
| ISIN: | DE0006450000 |
| WKN: | 645000 |
| Indices: | SDAX, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1253018 |
| End of News | DGAP News Service |
|
|
1253018 30.11.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
